Bruker (NASDAQ:BRKR) Given New $80.00 Price Target at Bank of America

Bruker (NASDAQ:BRKR) had its target price hoisted by stock analysts at Bank of America from $78.00 to $80.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Bank of America‘s price target indicates a potential upside of 38.58% from the company’s current price.

BRKR has been the subject of several other research reports. Citigroup cut their price target on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target for the company in a report on Thursday, December 5th. TD Cowen cut their price target on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Finally, UBS Group began coverage on Bruker in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price objective on the stock. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $74.70.

Bruker Price Performance

NASDAQ BRKR opened at $57.73 on Friday. The stock has a 50-day simple moving average of $58.83 and a 200 day simple moving average of $62.78. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66. The stock has a market capitalization of $8.75 billion, a PE ratio of 27.75, a P/E/G ratio of 4.00 and a beta of 1.18. Bruker has a twelve month low of $48.07 and a twelve month high of $94.86.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The company’s revenue was up 16.4% on a year-over-year basis. During the same period last year, the company earned $0.74 EPS. Research analysts anticipate that Bruker will post 2.4 EPS for the current year.

Insider Buying and Selling

In other Bruker news, CEO Frank H. Laukien purchased 100,000 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the transaction, the chief executive officer now directly owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 28.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bruker

Large investors have recently bought and sold shares of the business. First Horizon Advisors Inc. boosted its position in Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after buying an additional 218 shares during the last quarter. True Wealth Design LLC boosted its position in Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after buying an additional 510 shares during the last quarter. UMB Bank n.a. boosted its position in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after buying an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd bought a new position in Bruker in the 2nd quarter valued at $52,000. Finally, GAMMA Investing LLC boosted its position in Bruker by 81.0% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after buying an additional 388 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.